FDA approves Novo Nordisk's semaglutide as obesity treatment

The US FDA has given the thumbs-up to Novo Nordisk's semaglutide as an injection-based treatment for obesity. This paves the way for massive sales for the Danish pharmaceutical company.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR

There is an air of celebration at Novo Nordisk's headquarters, as the US Food and Drug Administration (FDA) has just approved the pharmaceutical company’s application for the use of semaglutide as a treatment for obesity marketed as Wegovy.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading